This week’s CLL update on the cllsociety.org is the first part of my interview with Professor Hallek on possible drug combinations using new and old therapies in the hope of being able to offer long term disease control (he won’t use the world cure quite yet) with relatively short term therapies.
Professor Hallek heads up the important and innovative German CLL Study Group that has made enormous contributions to our understanding of how to best treat our CLL, so I listen carefully to all he has to say.
He has realistic concerns about prospect of lifelong therapies and points out some of the unpleasant truths about the limitations of treatments with signal blockers such as ibrutinib or idelalisib.
But he says some ideas of what to do about those issues
To read my commentary and review and hear the interview, please click her in the past conference section of our website ( cllsociety.org/conference-c... ).
We are all in this together.